ATAI Life Sciences BV (ATAI)

Currency in USD
3.740
-0.140(-3.61%)
Closed·
After Hours
3.790+0.050(+1.34%)
·
ATAI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
Fair Value
Day's Range
3.7004.000
52 wk Range
1.0304.000
Key Statistics
Prev. Close
3.88
Open
4
Day's Range
3.7-4
52 wk Range
1.03-4
Volume
7.4M
Average Volume (3m)
4.19M
1-Year Change
147.68%
Book Value / Share
0.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.833
Upside
+162.92%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

ATAI Life Sciences BV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

ATAI Life Sciences BV Company Profile

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Compare ATAI to Peers and Sector

Metrics to compare
ATAI
Peers
Sector
Relationship
P/E Ratio
−5.3x−1.2x−0.5x
PEG Ratio
0.02−0.010.00
Price/Book
5.2x2.0x2.6x
Price / LTM Sales
425.9x2.5x3.2x
Upside (Analyst Target)
157.7%159.3%40.5%
Fair Value Upside
Unlock16.3%4.4%Unlock

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.833
(+162.92% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.15 / -0.1589
Revenue / Forecast
1.56M / --
EPS Revisions
Last 90 days

ATAI Income Statement

People Also Watch

2.140
ONDS
-1.83%
51.030
SMR
+6.65%
7.800
BBAI
-1.64%
61.56
MP
+0.69%
14.20
OSCR
-10.52%

FAQ

What Stock Exchange Does ATAI Life Sciences BV Trade On?

ATAI Life Sciences BV is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ATAI Life Sciences BV?

The stock symbol for ATAI Life Sciences BV is "ATAI."

What Is the ATAI Life Sciences BV Market Cap?

As of today, ATAI Life Sciences BV market cap is 791.30M.

What Is ATAI Life Sciences BV's Earnings Per Share (TTM)?

The ATAI Life Sciences BV EPS (TTM) is -0.91.

When Is the Next ATAI Life Sciences BV Earnings Date?

ATAI Life Sciences BV will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is ATAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ATAI Life Sciences BV Stock Split?

ATAI Life Sciences BV has split 0 times.

How Many Employees Does ATAI Life Sciences BV Have?

ATAI Life Sciences BV has 54 employees.

What is the current trading status of ATAI Life Sciences BV (ATAI)?

As of 25 Jul 2025, ATAI Life Sciences BV (ATAI) is trading at a price of 3.74, with a previous close of 3.88. The stock has fluctuated within a day range of 3.70 to 4.00, while its 52-week range spans from 1.03 to 4.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.